The EPO granted Arrowhead Pharmaceuticals patent EP4029941A1 for RNAi-based compositions targeting the LPA gene, which is associated with cardiovascular disease risk. The patent application includes claims covering the molecular constructs, delivery mechanisms, and therapeutic applications for reducing LPA protein expression. Designated states include all major EU economies (DE, FR, GB, IT, ES) plus Switzerland, Norway, and other EPC member states.

Patent holders and licensees should verify freedom-to-operate for any LPA-targeting therapeutics in these designated territories before commercial development. Generic pharmaceutical companies and research institutions should assess whether their LPA gene inhibition programs may infringe these claims. The patent term extends 20 years from the priority date.